{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=SAb+Biotherapeutics%2C+Inc.",
    "query": {
      "sponsor": "SAb Biotherapeutics, Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T10:18:10.998Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04518410",
      "title": "ACTIV-2: A Study for Outpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "bamlanivimab 7000mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BRII-196+BRII-198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SNG001",
          "type": "DRUG"
        },
        {
          "name": "Camostat",
          "type": "DRUG"
        },
        {
          "name": "BMS-986414 + BMS-986413",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (3,840 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (10,240 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CASIRIVIMAB + IMDEVIMAB",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 7000mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 700mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BRII-196+BRII-198",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SNG001",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Camostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (low dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BMS-986414 + BMS-986413",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IM)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (high dose)",
          "type": "DRUG"
        },
        {
          "name": "bamlanivimab 700mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4044,
      "start_date": "2020-08-19",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-10-06T10:18:10.998Z",
      "location_count": 207,
      "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04518410"
    },
    {
      "nct_id": "NCT02788188",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Middle East Respiratory Syndrome Coronavirus"
      ],
      "interventions": [
        {
          "name": "SAB-301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal (9%) Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 38,
      "start_date": "2016-05-28",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2018-06-12",
      "last_synced_at": "2026-10-06T10:18:10.998Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788188"
    },
    {
      "nct_id": "NCT06435936",
      "title": "A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PHA1A"
      ],
      "interventions": [
        {
          "name": "Single Ascending Dose of SAB-176",
          "type": "DRUG"
        },
        {
          "name": "Single Ascending Dose of Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2024-04-22",
      "completion_date": "2025-02-01",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-06T10:18:10.998Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06435936"
    },
    {
      "nct_id": "NCT07187531",
      "title": "SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "High Dose SAB-142",
          "type": "DRUG"
        },
        {
          "name": "Low Dose SAB-142",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "5 Years to 40 Years"
      },
      "enrollment_count": 159,
      "start_date": "2025-11-25",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-06T10:18:10.998Z",
      "location_count": 23,
      "location_summary": "San Francisco, California • San Jose, California • Aurora, Colorado + 20 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07187531"
    },
    {
      "nct_id": "NCT04469179",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV2"
      ],
      "interventions": [
        {
          "name": "SAB-185",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 21,
      "start_date": "2020-08-20",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-10-06T10:18:10.998Z",
      "location_count": 3,
      "location_summary": "Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04469179"
    },
    {
      "nct_id": "NCT04468958",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV2"
      ],
      "interventions": [
        {
          "name": "SAB-185",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-07-01",
      "completion_date": "2020-12-23",
      "has_results": false,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-10-06T10:18:10.998Z",
      "location_count": 3,
      "location_summary": "Wichita, Kansas • Syracuse, New York • San Antonio, Texas",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04468958"
    },
    {
      "nct_id": "NCT04471038",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza Type A",
        "Influenza Type B",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "SAB-176",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 27,
      "start_date": "2020-07-29",
      "completion_date": "2021-04-19",
      "has_results": true,
      "last_update_posted_date": "2025-01-06",
      "last_synced_at": "2026-10-06T10:18:10.998Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04471038"
    },
    {
      "nct_id": "NCT07670650",
      "title": "PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes (T1D)"
      ],
      "interventions": [
        {
          "name": "SAB-142",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "5 Years to 40 Years"
      },
      "enrollment_count": 108,
      "start_date": "2026-09-01",
      "completion_date": "2030-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-06T10:18:10.998Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07670650"
    }
  ]
}